RDHL — Redhill Biopharma Share News
0.000.00%
Last trade - 00:00- $3.76m
- -$0.32m
- $0.29m
Brief: RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
Brief: RedHill Biopharma Enters Into Purchase Agreement With Alumni Capital LP For Sale Of Up To $10 Million ADS - SEC Filing
Brief: Redhill Biopharma - Secures Kukbo Asset Freeze After $8.25 Million Judgment
Brief: Redhill Biopharma Secures Allowance Of Key Chinese Patent Application For Proprietary COVID-19 Treatment, RHB-107
Brief: RedHill Biopharma To Submit FDA-Approved Talicia For UK Marketing Authorisation
Brief: RedHill Biopharma Advances Its Groundbreaking Late-Stage Crohn's Disease Program Building On Statistically Significant Positive Rhb-104 Phase 3 Result
Brief: RedHill Biopharma Awarded Judgment Of Approximately $8 Million Plus Costs By New York Supreme Court
Brief: RedHill Biopharma Secures US Government Funding Through BARDA To Advance Opaganib For Ebola Treatment
RedHill Biopharma rises on positive preclinical results from obesity drug
Brief: Redhill Biopharma Announces Plan To Implement ADS Ratio Change
Brief: Redhill Biopharma Strengthens Cash Balance, Settles Obligations And Removes Talicia Lien
Brief: RedHill Biopharma Terminates License Agreement for Aemcolo®
Brief: RedHill Announces New Patent Covering Opaganib In Combination With Immune Checkpoint Inhibitors
Brief: Redhill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
Brief: Redhill Provides Research And Development Update
RedHill up after selling constipation drug rights to clear debt
RedHill Biopharma rises on U.S. patent for lung disease drug
Refile: BUZZ-RedHill up as oral drug shows promise against radiation injury in study
Redhill Biopharma rises on new U.S. patent for COVID drug